The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Almost no chance of this being shorted..... far too illiquid. I would expect that it will retrace to 26/ 27. I have seen it all the way up to 52 in the last 5 years and firmly believe that it will go higher than that long term. It's a good company, with sound pharma investments, plus a successful hotel. Once they get more exposure over here who knows where it may go. There are some high brow investors, including Hendersons, who firmly believe the story. I have built up a big position over time and am in for the long haul. They report on Friday, which may have some bearing on the move. hopefully some cheer there
I can see on the 6 month chart that this dropped almost freefall from a resistance at around 26p+ starting in Jan with not much driving aside from, as you say, a sell off so maybe one or a few big sellers moving this down to short it? What is clear is that the price has broken upwards out of a downwards wedge on the chart showing a significant up trend forming today, so perhaps we are looking for a fast recovery back to previous resistance at 26p+, that is how the charts are looking. What are your thoughts about price target short term and beyond and what do you see moving this up significantly in the mid term... what are the big projects that could sky rocket the firm? I am in anyway, looking at 26p price target and then maybe top slice and take a long postition....
Did you miss the downward movement from 28? Technical situation in the market, which was long. Sellers come in and due to lack of liquidity price hammered. I can only suggest some of the sellers taken out and price trying to return to more reasonable level. This is a good company but doesn't have enough broker exposure. Expect to see a new broker appointed to try and change the situation.
No news, nothing in the chat, trends and technicals all look negative... I am lost to why this is trading upwards so strongly on basically no news.... help me out someone, what did I miss?
Cathay International Holdings Ld 03 September 2013 Cathay International Holdings Limited ("Cathay" or the "Company") Lansenand Haotian Sign Plant Extract Supply Agreement Further Synergies Leveraged between Key Portfolio Companies Hong Kong, 3 September 2013 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC"), today announces that Liwah Zhiti, an indirect subsidiary of Cathay under the Lansen Group, has signed an Entrusted Manufacturing Framework Agreement for the supply of plant extract products with Yangling Haotian and Xian Haotian, indirect wholly-owned subsidiaries of Cathay under the Haotian Group. Today's transaction is in line with a key management objective stated in the Company's recent interim results to create further synergies across the Group. The agreement leverages key synergies between Haotian's and Lansen's plant extract business in manufacturing, R&D and marketing. Under the terms of the agreement, which is deemed to be in the ordinary course of business for Cathay International Holdings, Yangling Haotian and Xian Haotian will supply plant extract products on an order by order basis to Liwah Zhiti. The selling price per unit will be determined by reference to the prevailing market prices for the products and the agreement is valid until December 2014. The maximum value of the transactions contemplated under the agreement will be approximately USD9.2 million (RMB56 million), of which the annual capped value for the year ending 31 December 2013 will be approximately USD4.6 million (RMB28 million) and for the year ending 31 December 2014, approximately USD4.6 million (RMB28 million). Mr. Lee Jin-Yi, Chief Executive Officer of Cathay commented:"A key aim of Cathay International Holdings, stated at the time of our interim results, is to create further synergies across our portfolio companies. Today's agreement is an example of one of many potential cross-company transactions which will lead to greater efficiencies and enhanced benefits for the Group's operations." -ENDS- For further enquiries, please contact: Cathay International Holdings Limited Eric Siu (Finance Director) Tel: +852 2828 9289 Patrick Sung (Director and Controller) Consilium Strategic Communications
Cathay International Holdings: Peel Hunt reduces target price from 41p to 28p and downgrades to hold.
The business environment in second half of 2012 will continue to be challenging with the global economic uncertainty and slow growth in China and Chinese medical reforms proposing to lower drug prices would force the industry to further consolidate. Even with the softened economy, the China healthcare and pharmaceutical markets are projected to grow at 15-20% per annum in the foreseeable future. The outcome for the year as a whole is going to depend upon the Group continuing to benefit from the growth shown by Lansen as well as Haotian delivering an improved performance, which will be dependent upon the final phases of the inositol project being completed to plan. The Group continues to explore investment opportunities that would strategically fit into its existing businesses and compliment the overall product portfolio. Within Lansen, the investment focus will be on broadening its product portfolio in the rheumatology space via its current development product pipeline; and through potential business collaborations and product acquisitions; and expanding its sales and distribution network to second and third tier China cities. Botai will continue to work on the commercial launch of its product and on building a competitive market share.
Commenting on the interim results, Mr. Lee Jin-Yi, CEO of Cathay International Holdings Limited, said: "Despite the slow growth seen across China's economy, and also in the pharmaceutical sector, Cathay achieved 25.6% top-line growth in the first half this year. This significantly outperformed the local market and growth was largely driven by Lansen's core rheumatoid drug sales, the positive results of the repositioning of the hotel and a carefully managed cost base across the Group. Our performance was, however, dragged by Haotian. Haotian is going into the pre-operating phase of the inositol project, preparing for the full-scale operation. Botai is working towards market launch of its collagen injectable filler. While we have entered the second half of the year with a cautiously optimistic approach bolstered by the 15-20% projected growth rates for the healthcare and pharmaceutical market in China that should benefit Lansen; the outlook of the Group will also depend on Haotian's inositol project being completed to plan. We remain committed to exploring investment opportunities that strategically fit well with the Group's strategy and remain focused on driving our business forward in order to deliver value for our shareholders."
Hong Kong, 29 August 2012 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China, today announces its Interim Results for the six months ended 30 June 2012. Group · Revenues increased by 25.6% to USD48.4 million (2011: USD38.5 million) · Gross profit increased by 21.4% to USD24.4 million (2011: USD20.1 million) · Operating profit grew by 1.7% to USD3.8 million (2011: USD3.7 million) · Net profit decreased to USD2.2 million (2011: USD2.9 million)
http://www.investegate.co.uk/Article.aspx?id=201208290923069777K
. Peel Hunt initiates buy on Cathay International, target price 40p
100% down does that mean there not trading anymore or what?
CTI have ultra luxurious hotels in China and their share price is on the up but quickly just now. They sent their staff to England for training as butlers etc. Their share price 9p last week and 11.75 today - they say could be 20 soon. Just thought you might be interested especially as they do more than real estate